After publication of the original article [1], the authors noticed that the article contained some errors in the data presented within Table 1, Figs. 1 and 2, and Tables 2 and 3.
Fig. 1
Flow chart depicting the participation of subjects in the Korean Headache-Sleep Study
Fig. 2
Venn diagram for distribution of subjects with anxiety, depression and migraine
Table 1
Sociodemographic distribution of all survey participants, the total Korean population, and of cases identified as migraine, anxiety and depression
Survey participants N (%)
Total population N (%)
P
Migraine N, % (95 % CI)
Anxiety N, % (95 % CI)
Depression N, % (95 % CI)
Men
1345 (49.3)
17,584,365 (50.6)
0.854a
36, 2.7 (1.8–3.5)
109, 8.1 (6.6–9.6)
43, 3.2 (2.3–4.2)
Women
1350 (50.7)
17,198,350 (49.4)
107, 7.9 (6.5–9.4)
159, 11.8 (10.1–13.5)
73, 5.4 (4.2–6.6)
Age
19–29
542 (20.5)
7,717,947 (22.2)
0.917a
25, 4.5 (2.7–6.2)
53, 9.6 (7.2–12.1)
23, 4.1 (2.5–5.8)
30–39
604 (21.9)
8,349,487 (24.0)
42, 7.0 (4.9–9.1)
51, 8.7 (6.4–11.0)
32, 5.4 (4.6–7.3)
40–49
611 (23.1)
8,613,110 (24.8)
39, 6.5 (4.5–8.4)
67, 11.0 (8.5–13.5)
24, 4.0 (2.5–5.5)
50–59
529 (18.9)
6,167,505 (17.7)
22, 4.1 (2.4–5.9)
53, 9.9 (7.3–12.5)
22, 4.2 (2.5–6.0)
60–69
409 (15.6)
3,934,666 (11.3)
15, 3.9 (2.0–5.7)
14, 10.8 (7.8–13.8)
15, 3.7 (2.0–5.5)
Size of residential area
Large city
1248 (46.3)
16,776,771 (48.2)
0.921a
76, 6.1 (4.8–7.5)
130, 10.4 (8.7–12.1)
57, 4.6 (3.4–5.7)
Medium–to–small city
1186 (44.0)
15,164,345 (43.6)
48, 4.0 (2.9–5.2)
112, 9.5 (7.8–11.2)
47, 4.0 (2.9–5.1)
Rural area
261 (9.7)
2,841,599 (8.2)
19, 7.4 (4.2–10.6)
26, 10.0 (6.3–13.6)
12, 4.7 (2.1–7.3)
Education level
Middle school or less
393 (14.9)
6,608,716 (19.0)
0.752a
22, 5.5 (4.2–7.7)
55, 13.9 (10.5–17.4)
20, 5.2 (3.0–7.4)
High school
1208 (44.5)
15,234,829 (43.8)
60, 5.0 (3.8–6.3)
111, 9.2 (7.5–10.8)
49, 4.1 (3.0–5.2)
College or more
1068 (39.6)
12,939,170 (37.2)
60, 5.6 (4.3–7.0)
100, 9.5 (7.7–11.2)
47, 4.4 (3.2–5.7)
Not responded
26 (9.6)
1, 3.8 (0.0–11.8)
2, 8.0 (0.0–18.0)
0, 0.0 (0.0–0.0)
Total
2695 (100.0)
34,782,715 (100.0)
143, 5.3 (4.5–6.2)
268, 10.0 (8.8–11.1)
116, 4.3 (3.6–5.1)
aCompared gender, age group, size of residential area, and educational level distributions between the sample of the present study and total population of Korea
Table 2
Demographics, headache characteristics and associated symptoms of migraineurs according to anxiety and depression
Migraine subjects without anxiety or depression, N = 92
Migraine subjects with anxiety alone, N = 27
Migraine subjects with depression alone, N = 8
Migraine with anxiety and depression, N = 16
P-value
Demographics
Mean age ± SD (years)
40.4 ± 11.4
47.2 ± 14.5
42.1 ± 15.7
44.5 ± 18.4
0.131
Women, N (%)
71 (75.5)
21 (77.8)
7 (77.8)
13 (76.5)
0.995
Headache characteristics
Unilateral pain, N (%)
57 (60.6)
15 (53.6)
4 (44.4)
7 (41.2)
0.409
Pulsating quality, N (%)
72 (76.6)
21 (77.8)
7 (77.8)
12 (70.6)
0.950
Moderate-to-severe severity, N (%)
72 (75.8)
22 (81.5)
8 (88.9)
17 (100.0)
0.119
Aggravation by movement, N (%)
60 (63.8)
21 (77.8)
5 (55.6)
15 (88.2)
0.121
Associated symptoms
Nausea, N (%)
84 (88.4)
23 (82.1)
9 (100.0)
15 (88.2)
0.544
Vomiting, N (%)
33 (34.7)
15 (53.6)
3 (33.3)
8 (47.1)
0.288
Photophobia, N (%)
55 (57.9)
19 (70.4)
1 (11.1)
11 (64.7)
0.017
Phonophobia, N (%)
63 (67.0)
21 (77.8)
6 (66.7)
13 (76.5)
0.668
Osmophobia, N (%)
42 (44.7)
13 (48.1)
4 (44.4)
9 (46.3)
0.930
Table 3
Frequency, severity and impact of headache according to migraineurs’ anxiety and depression status
Migraine subjects without anxiety or depression, N = 92
Migraine subjects with anxiety alone, N = 27
Migraine subjects with depression alone, N = 8
Migraine subjects with anxiety and depression, N = 16
*Kruskal–Wallis one–way analysis of variance test among the four groups: migraine subjects without anxiety or depression, migraine subjects with anxiety alone, migraine subjects with depression alone and migraine subjects with anxiety and depression
1: migraine subjects without anxiety or depression; 2: migraine subjects with anxiety alone; 3: migraine subjects with depression alone; 4: migraine with anxiety and depression
×
×
The corrected versions are given in this erratum. The main findings of the original article are not affected after this correction. The authors apologise for any inconvenience this has caused.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.
Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.
